Testing a nutrient-boosting medication during cervical cancer treatment

Plain-English translation of NCT07338487 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated October 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing nanocrystalline megestrol acetate, a medication designed to help people with cervical cancer maintain their weight and muscle during concurrent chemotherapy and radiation treatment. The medication works by stimulating appetite and reducing inflammation in the body. Researchers believe this treatment could help prevent serious weight loss and malnutrition, which can worsen survival outcomes.

About one-third of cervical cancer patients develop severe malnutrition and muscle wasting during chemotherapy and radiation, and this weight loss is linked to significantly higher death rates. This medication has shown promise in other cancer types, but researchers want to test whether it can effectively help cervical cancer patients maintain their nutrition during their most intensive treatment phase.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with locally advanced cervical cancer (stage IB3, IIA2, IIB, or IVA) that cannot be treated with surgery alone
you are scheduled to receive chemotherapy combined with radiation therapy
you have adequate heart, kidney, and liver function based on blood tests
you are willing to take the study medication or placebo as assigned throughout your cancer treatment

You likely don't qualify if…

you are pregnant or breastfeeding
you have severely low blood counts, kidney function, or liver function
you have a heart condition with reduced heart pumping ability
you cannot attend regular study visits and follow the treatment plan
you are unable or unwilling to use effective contraception during and for four months after the study medication

What participation looks like

You will be randomly assigned to receive either the medication or a placebo (inactive pill) by mouth while you undergo your regular chemotherapy and radiation treatment. You will continue taking your assigned treatment throughout your cancer therapy and attend regular clinic visits for blood tests, weight checks, and health assessments. The study involves 88 women total and will track how well the medication helps you maintain your nutrition and quality of life during treatment.

AI-generated summary from trial data · Oct 12, 2026 · Not medical advice

Trial locations(1 site)

China

Xiangya Second Hospital of Central South University, Changsha, Hunan

Key details

Phase

Safety & dosing

Sponsor

Second Xiangya Hospital of Central South University

Enrollment target

~88 participants

Started

April 2026

Primary completion

December 2026

Age range

18 Years and older

Sex

Female only

Last updated on clinicaltrials.gov in April 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

jingjing Wang

Second Xiangya Hospital of Central South University

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov